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Role of Wall Teichoic Acids in Staphylococcus
aureus Endophthalmitis
Takashi Suzuki,1 Jennifer Campbell,2 Jonathan G. Swoboda,2 Suzanne Walker,2
and Michael S. Gilmore1,2
PURPOSE. Wall teichoic acids (WTAs) are major polyanionic
polymer components of the cell wall of Staphylococcus au-
reus. However, little is known about their role at the host–
pathogen interface, especially in endophthalmitis. This study
was designed to investigate the extent to which WTAs contrib-
ute to the pathogenicity of S. aureus in models of endophthal-
mitis and to determine whether there would be value in tar-
geting their biosynthesis as a new therapeutic approach.
METHODS. S. aureus RN6390 and its isogenic WTA-null mutant
(RN6390tarO) were used to evaluate the role of WTAs in
endophthalmitis. RN6390 and RN6390tarO were cultured in
bovine vitreous humor (VH) in vitro or inoculated into the
vitreous chamber of C57B6 mice. Changes in the number of
bacteria, organ function as determined by electroretinography
(ERG), and histopathologic changes were assessed throughout
the course of infection. In addition, the efficacy of WTA bio-
synthesis inhibitors in VH in vitro was examined.
RESULTS. It was observed that a component of VH synergized
with WTA biosynthesis inhibitors in vitro and killed the S.
aureus. This effect was also seen when mutants incapable of
expressing WTA were exposed to VH. The killing activity of
VH was lost on treatment with a protease inhibitor.
RN6390tarO could not survive in mouse eyes and did not
affect organ function, nor was it able to establish endophthal-
mitis.
CONCLUSIONS. WTAs are essential cellular constituents for the
manifestation of virulence by S. aureus in endophthalmitis,
and appears to be a viable target for treating the endophthal-
mitis caused by S. aureus strains. (Invest Ophthalmol Vis Sci.
2011;52:3187–3192) DOI:10.1167/iovs.10-6558
Bacterial endophthalmitis is a severe and sight-threateningocular infection.1 It is characterized by massive inflamma-
tion and tissue damage caused both by bacterial infection and
subsequent immune response. Bacterial endophthalmitis usu-
ally occurs in the context of ocular surgery, trauma, microbial
keratitis, or the hematogenous spread of the organism to the
eye. Postoperative endophthalmitis is a severe complication of
ocular surgery, such as cataract surgery, glaucoma surgery, or
vitrectomy.1 Although the technical procedures used in sur-
gery are improving, the incidence of endophthalmitis has not
changed and may be increasing.2
Staphylococcus aureus is a commensal species that colo-
nizes the mucosa and skin adjacent to the eye, and as a result,
often contaminates surgical sites and leads to endophthalmi-
tis.1,3 Methicillin resistance in S. aureus is on the rise in the
community, which in the United States has been associated
with the proliferation of the USA300 MRSA (methicillin-resis-
tant S. aureus) lineage,4,5 which likely has contributed to the
increased incidence of endophthalmitis caused by MRSA.6,7
Although fluoroquinolones and cephalosporins are widely
used for the treatment and prevention of S. aureus endoph-
thalmitis, they are less efficacious against MRSA.6,7 Moreover,
S. aureus recently acquired resistance to vancomycin, a drug
of last resort.8–10 Because of the rapid emergence of resistant
strains, new antibacterial targets that lack cross-resistance with
drugs currently in use to treat S. aureus infection are urgently
needed.
A possible therapeutic target that is now being explored is
S. aureus wall teichoic acid (WTA) biosynthesis. WTAs are
anionic polymers composed of repeating units of ribitol-phos-
phate that are covalently linked to the bacterial cell wall in
many Gram-positive pathogens.11 They influence critical prop-
erties of the cell envelope, including charge, cation binding,
tensile strength, rigidity, and permeability.11 WTAs are not
required for the growth of S. aureus in vitro, but are needed to
establish infection in most animal models.12–15
S. aureus WTA polymer biosynthesis is performed by the
Tar enzymes.11,16 Of interest, this biosynthetic pathway con-
tains two classes of targets: antivirulence targets and antibac-
terial targets. The first two genes in the pathway (tarO or tarA)
can be knocked out, and the resulting mutants are viable in
vitro, making the products of these genes potential antiviru-
lence targets. However, genes downstream of tarA in the WTA
pathway cannot be deleted in a wild-type background,16 mak-
ing them antibacterial targets in wild-type strains. However, if
flux through the pathway is diverted, either through genetic
mutation (of tarO or tarA) or pharmacologic inhibition of TarO
by the natural product tunicamycin, these downstream en-
zymes become expendable, suggesting that the essentiality of
these downstream functions results from the accumulation of
WTA biosynthetic intermediates in the pathway. The charac-
terization of the first small-molecule inhibitor of an antibacterial
target within the WTA biosynthetic pathway was recently re-
ported by one of our groups (SW).17 The compound, 1835F03,
inhibits TarG, the transmembrane component of the ABC trans-
porter that exports WTAs to the cell surface.17 A structure–
activity relationship study of 1835F03 led to the discovery of a
second-generation analogue, targocil, which is 10 times more
potent.18 Because blocking polymer synthesis at the beginning
of the pathway renders TarG nonessential, these WTA inhibi-
tors generate mutants in which WTAs are no longer expressed.
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Thus, they can be regarded as both antibiotics and antiviru-
lence factor agents.17
Although the roles of WTAs have been investigated in S.
aureus colonization of epithelial and endothelial cells,12–15 the
role of WTAs in vivo in eye infection and the extent to which
this pathway could represent a viable treatment target have not
yet been explored. In the present study, we assessed the
necessity for WTA biosynthesis during S. aureus endophthal-
mitis, both in vitro and in vivo. The WTA transport inhibitor,
targocil, was previously shown to halt S. aureus growth
through a bacteriostatic mechanism.17,18 In this study, we
showed the surprising finding that targocil treatment killed S.
aureus in vitro in vitreous humor (VH). Further, we found that
a WTA-deficient mutant cannot survive in VH in vitro or in
vivo, and as a result WTA-deficient mutants are highly attenu-
ated, with little capacity to cause endophthalmitis.
MATERIALS AND METHODS
Bacteria and Growth Conditions
The S. aureus strains used in this study are listed in Table 1. The
WTA-deficient tarO mutant (RN6390tarO) was generated from
RN6390 by allelic exchange with a tetracycline resistance marker.22,23
RN6390tarO is defective in WTA production because of deletion of
the first essential enzyme in the pathway. For reasons yet unknown,
the mutant was subtly affected in toxin production. Supernatants from
overnight cultures of RN6390tarO were found to be one half to one
fourth that of RN6390. In addition RN4220 PspactarO, a strain that
expresses tarO under the control of an isopropyl -D-1-thiogalactopy-
ranoside (IPTG)-inducible promoter, was used to verify the role of
TarO.17 S. aureus strains were grown in tryptic soy broth (TSB) at
37°C, unless otherwise noted. Tetracycline (Tc; 2.5 g/mL) and eryth-
romycin (Em; 10 g/mL) were used for selection where appropriate.
To inhibit various steps in WTA biosynthesis, targocil and tunicamycin
were dissolved in dimethyl sulfoxide (DMSO) and stored at 20°C. In
controls and experimental groups, final concentrations of DMSO were
adjusted to 1% in all assays, unless otherwise stated.
Assessment of Activity in Vitreous Humor
Bovine eyes obtained from Sierra for Medical Science (Whittier, CA)
were used within 24 hours of enucleation and stored at 4°C before use.
VH was aspirated with a syringe fitted with an 18-gauge needle.
Liquefied portions of the vitreous were carefully aspirated, taking care
to avoid areas of adhesion to the retina and other tissues. The VH was
filtered through a GD/X sterile 0.45 m PES syringe filter (Whatman,
Clifton, NJ) and stored at 20°C. Each experiment used vitreous from
an individual eye.
Animal Care and Use
Female C57BL/6J mice were obtained from the Charles River Labora-
tory (Boston, MA). All animals were humanely treated according to the
guidelines of the ARVO Statement for the Use of Animals in Ophthal-
mic and Vision Research. All procedures involving mice were ap-
proved by the Schepens Eye Research Institute Institutional Animal
Care and Use Committee (IACUC). When appropriate, the mice were
anesthetized by intraperitoneal injection of ketamine (62.5 mg/kg) and
xylazine (12.5 mg/kg). The animals were euthanatized at the appropri-
ate time points by CO2 asphyxiation after anesthesia.
Bacterial Growth in Vitreous Humor In Vitro
Targocil and tunicamycin were used as WTA biosynthesis inhibitors.
Targocil inhibits a late step in WTA biosynthesis and stops S. aureus
growth bacteriostatically.18 The minimum inhibitory concentration
(MIC) of targocil against RN6390 is 1 g/mL. Tunicamycin is an
inhibitor of a large class of enzymes that couple sugar phosphates to
membrane-embedded lipid phosphates,24 and 1 g/mL tunicamycin
inhibits WTA production by S. aureus in vitro without affecting bac-
terial growth rates.17 An overnight culture of S. aureus RN6390 was
diluted to approximately 104 CFU in 100 L of VH or brain–heart
infusion (BHI) medium containing 1% DMSO, 5 MIC (5 g/mL)
targocil, or 1 g/mL tunicamycin and cultured at 37°C statically for 24
hours. Bacteria were enumerated by plating a serial 10-fold dilution. To
examine rates of growth of the RN6390 and RN6390tarO strains, we
diluted overnight cultures to approximately 105 CFU in 1 mL of VH or
BHI medium and cultured the bacteria at 37°C statically. The bacteria
were enumerated by serial dilution at each time point. In addition
RN4220 PspactarO was tested for bacterial growth in VH. Dilutions of
an overnight culture of S. aureus RN4220 wild-type or PspactarO were
inoculated into VH, with or without 1 mM IPTG, and bacterial growth
was monitored over a 24-hour period. Experiments were performed
three times independently.
Transmission Electron Microscopy
RN6390tarO or RN6390 were inoculated to approximately 109 CFU
per milliliter of VH and cultured at 37°C for 6 hours. The cells were
collected at 0 or 6 hours, fixed in Karnovsky’s fixative (2% paraformal-
dehyde and 2.5% glutaraldehyde in cacodylate buffer [pH 7.4]), and
processed for transmission electron microscopy (TEM) by using stan-
dard procedures described elsewhere.25 For TEM, 60- to 90-Å sections
were obtained, viewed, and photographed (model 410 microscope;
Philips Electronics NV, Eindhoven, The Netherlands). Diameters of all
cells within three microscopic fields (50–80 cells per strain) were
measured with ImageJ software (developed by Wayne Rasband, Na-
tional Institutes of Health, Bethesda, MD; available at http://rsb.info.
nih.gov/ij/index.html).
Effect of Enzyme or Chemical Treatment on the
Killing Ability of VH
Bacterial growth was examined in VH or VH treated in various ways
to illuminate the basis for killing. In one case, VH was pretreated
with 100 g/mL protease K (New England Biolabs Inc., Beverly,
MA) at 37°C overnight and then boiled for 5 minutes to inactivate
the added protease. VH was also pretreated with protease inhibitors
for 1 hour at 37°C at the following concentrations: 104 mM 4-(2-
aminoethyl)benzenesulfonylfluoride (AEBSF), 1.4 mM trans-
epoxysuccinyl-L-leucylamido(4-guanidino)butane (E-64), 4 mM
bestatin, and 1 protease inhibitor (PI) cocktail, EDTA-free (Sigma-
Aldrich, Poole, UK). DMSO, the diluent for all inhibitors, was ad-
justed to 1% in VH and used as control. Growth of RN6390tarO in
variously treated VH was examined for 24 hours.
TABLE 1. Bacterial Strains
Strain Genotype and/or Phenotype Reference
RN6390 Prophage-cured derivative of NCTC 8325 19
RN4220 A mutant of NCTC 8325–4 that accepts foreign DNA partial agr defect 20
RN6390tarO RN6390 tarO::tetL This study
RN4220tarO RN4220 tarO 21
PspactarO RN4220 tarO::tetL [geh:: (pCL25int-PspactarO) Em
r] 17
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Murine Model of Endophthalmitis
The vitreous of eyes of 6- to 8-week-old mice were inoculated by
insertion of a borosilicate microcapillary, pulled to a tip size of 50 m,
immediately behind the limbus-parallel conjunctival vessels, corre-
sponding to the narrow murine pars plana, essentially as de-
scribed.26,27 The right eyes of the mice were injected with 0.5 L of a
bacterial suspension containing 5000 CFU of either S. aureus RN6390
or RN6390tarO diluted in physiologic saline. The left eye of each
mouse was left untreated and served as an internal control for electro-
retinography (ERG) studies. Experiments were performed with a min-
imum of four animals per experimental group and repeated at least
twice.
Quantification of Bacterial Growth
Eyes were enucleated after euthanatization, and the residual adnexal
tissue was trimmed before the eyes were rinsed and placed in cold
phosphate-buffered saline (PBS). The enucleated eyes were disrupted
and homogenized to release bacteria for enumeration by bead-
beating with 1.0-mm glass beads (FastPrep; Thermo Scientific,
Waltham, MA) in 1 mL PBS for 1 minute at maximum speed. The
homogenates were serially diluted, plated onto BHI agar plates, and
incubated overnight at 37°C.
Electroretinography
ERG was performed on the mice at 24 and 48 hours after inoculation,
using a protocol modified slightly from those previously published.26,27
Briefly, the mice were dark adapted for at least 4 hours and then
anesthetized. The pupils were dilated using 1% tropicamide ophthal-
mic solution (Bausch & Lomb, Tampa, FL). After anesthesia, the body
temperature was maintained at 37°C with a microwave heating pad.
Gold wire electrodes (0.25 mm; Alfa Aesar, Ward Hill, MA) were placed
on the cornea after application of a hypromellose ophthalmic prism
solution (Akorn, Inc. Buffalo Grove, IL) and connected to a visual
electrodiagnostic system (UTAS-E 3000; LKC Technologies, Gaithers-
burg, MD). Needle electrodes placed in the anterior scalp and the tail
served as reference and ground leads, respectively. The b-wave ampli-
tude (measured from the trough of the a-wave to the peak of the
b-wave) in response to a bright flash in a Ganzfeld illumination sphere
was recorded for the injected right eye and the contralateral (internal-
control) left eye simultaneously. A total of 30 readings at 0.6 cd-s/m2
flash intensity with a 1-second interval between flashes were taken and
averaged. The retinal function was defined as the ratio of the b-wave
amplitude (from the trough of the a-wave to the peak of the b-wave) of
the experimentally treated eye divided by the value for the contralat-
eral untreated eye.
Histologic Analysis
The mice were euthanatized 48 hours after infection, and the eyes
were enucleated with Stevens curved, sharp-tip scissors. The eyes
were fixed in 10% buffered formalin, embedded in paraffin, sectioned,
and stained with hematoxylin and eosin (HE).
Statistical Analysis
Data were analyzed by Student’s t-test for significance. Values of P 
0.05 were considered significant.
RESULTS
Bacterial Growth in Vitreous Humor In Vitro
The antibacterial activity of targocil in VH was examined ini-
tially. As expected, targocil readily inhibited the growth of
RN6390 at levels five times the in vitro MIC in BHI at 24 hours
(Fig. 1A). Unexpectedly, however, targocil at identical levels
reduced the number of viable bacteria in VH (Fig. 1A). The
TarO inhibitor, tunicamycin, which does not inhibit bacterial
growth at 1 g/mL in BHI, also was capable of killing S. aureus
in VH (Fig. 1B). Thus, a component of VH synergized with
compounds that inhibit steps in the WTA biosynthetic path-
way, one bacteriostatic and the other permissive for growth in
vitro, killed the S. aureus. Similar behavior was observed for
strains in which specific deletions were engineered into the
tarO gene, providing independent verification of the mecha-
nism. Growth patterns for RN6390 and RN6390tarO in BHI
broth were similar, whereas the number of viable bacteria for
only RN6390tarO was reduced in VH (Fig. 2). To prove the
role of WTAs in this effect, we used an S. aureus strain
expressing tarO from an IPTG-inducible promoter, confirming
that WTAs are required for bacterial growth and survival in VH.
The growth of the wild-type strain was not influenced by the
presence of IPTG. However, the IPTG-inducible Pspac strain
was killed in VH without IPTG induction (WTA), but was
rescued by IPTG induction of WTA synthesis (Fig. 3).
Ultrastructural Comparison
The loss of WTA had a profound effect on cell morphology in
VH, as observed by TEM (Fig. 4). The WTA-deficient mutant
cultured in BHI showed a rough surface with many surface
protrusions, as previously reported (Fig. 4B, right).28 The av-
erage longitudinal diameter of RN6390 and RN6390tarO at 0
hours was 0.74  0.10 and 0.75  0.14 m, respectively. The
WTA-deficient mutant exposed to VH for 6 hours, however,
FIGURE 1. Efficacy of WTA inhibitors in VH. (A) Growth change
(log CFU/mL) of RN6390 bacteria after a 24-hour incubation with
1% DMSO or 5 g/mL targocil in BHI or VH is shown. Targocil
inhibited bacterial growth in BHI, but killed S. aureus in VH. (B)
Growth change (log CFU/mL) of RN6390 bacteria, which were treated
with 1% DMSO or 1 g/mL tunicamycin for 24 hours in BHI or VH, is
shown. At the concentration tested, tunicamycin did not inhibit bacterial
growth in BHI. The number of tunicamycin-treated bacteria present in VH
decreased. Data are expressed as the mean  SEM (n  3).
FIGURE 2. Growth curve of RN6390 (F) and RN6390tarO (E) in BHI
(A) or VH (B). Although RN6390tarO grew as well as the parental strain
in BHI, it was killed in VH. Data are expressed as the mean  SEM (n 
3). *P 0.05, **P 0.001 (in comparison with RN6390tarO at 0 hours).
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contained a subpopulation of strikingly enlarged or irregularly
shaped cells, compared with the wild-type (Fig. 4C). The av-
erage longitudinal diameter of RN6390 in VH at 6 hours was
0.69  0.06 m compared with 0.91  0.19 m for
RN6390tarO, corresponding to an average increase of 32%
(P  0.001, t-test). Some WTA-null mutant cells show aberrant
septal positioning, additional septal initiation parallel to already
existing septa (Fig. 4D, middle), and disruption and lysis (Fig.
4D, right). These aberrations were rare or absent in wild-type
cells (Fig. 4D, left).
Killing of WTA-Deficient S. aureus Relates to
Endogenous Protease Activity
Bovine vitreous was treated in various ways, to collect evi-
dence to explain the unexpected synergistic killing of WTA-
deficient S. aureus. Boiling for 5 minutes did not eliminate the
synergistic killing activity. However, treatment with protease K
abolished the activity, implicating a heat-stable, protein-based
activity (Fig. 5A). Proteases in VH were inhibited using a PI
cocktail. When VH was preincubated with this mixture for 1
hour, synergistic killing of the WTA-deficient mutant was sig-
nificantly inhibited (Fig. 5B). Although other inhibitors such as
a broad-spectrum cysteine protease inhibitor (E64) and the
aminopeptidase inhibitor (bestatin) had no effect on synergis-
tic killing in VH, addition of a serine protease inhibitor (AEBSF)
eliminated the killing and permitted growth of WTA-null mu-
tants in VH (Fig. 5C). This is prima facie evidence that WTA
provide S. aureus with protection from lethal activity that
relates to an endogenous protease. The nature of that lethal
activity is the subject of ongoing study.
Virulence in Endophthalmitis
Ocular infections established with RN6390 resulted in a signif-
icantly greater reduction of b-wave amplitude than did infec-
tion with RN6390tarO, from 24 to 48 hours after inoculation
(P  0.001; Fig. 6A). All eyes infected with RN6390 became
unresponsive to ERG 24 to 48 hours after inoculation. In
contrast, the WTA-deficient mutant RN6390tarO did not es-
tablish endophthalmitis and did not result in loss of organ
function, as measured by ERG. The number of recovered
RN6390 increased over the course of the infection, whereas
FIGURE 3. The regulation of tarO by the lac repressor binding to the
Pspac operator. Induction of tarO occurred on addition of IPTG. Growth of
RN4220 and the IPTG-inducible tarO strain in the absence and presence
of IPTG in VH showed that WTA expression (through IPTG-mediated
TarO induction) protected S. aureus from the VH killing effect.
FIGURE 4. Cell morphology in VH. TEM images of RN6390 and
RN6390tarO in VH at 0 (A, B) and 6 (C, D) hours at a lower magnifica-
tion (A, C) and a higher magnification (B, D). Black arrowheads: rough
surface with many surface protrusions. White arrowheads: initiation of
parallel septa observed in the WTA-null mutant, RN6390tarO, in VH at
6 hours.
FIGURE 5. Effect of enzyme or chemical pretreatment on the killing
ability of VH. (A) Growth change (log CFU/mL) of RN6390tarO after
a 24-hour incubation in VH; heated VH and VH treated with protease K are
shown. Protease K treatment diminished the VH killing effect. (B) Growth
change (log CFU/mL) of RN6390tarO after a 24-hour incubation in
VH treated with 1% DMSO or a protease inhibitor (PI) cocktail are shown.
PI-treated VH lost its ability to kill RN6390tarO. (C) Growth change
(log CFU/mL) of RN6390tarO after a 24-hour incubation in VH
treated with 1% DMSO or protease inhibitors is shown. Only VH treated
with the serine protease AEBSF lost its ability to kill RN6390tarO. Data
are expressed as the mean  SEM (n  3).
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that of RN6390tarO decreased from 24 to 48 hours after
inoculation (Fig. 6B). Histologically, eyes infected with
RN6390 showed signs of disruption of the retinal layers with
massive infiltration of the vitreous cavity by inflammatory cells.
In contrast, the eyes infected with RN6390tarO showed only
sparsely distributed inflammatory cells in the vitreous body.
The retinas of these eyes appeared normal (Fig. 6C).
DISCUSSION
Recent work has shown that WTAs are dispensable for growth
under laboratory conditions.12,16,29 However, little is known
about the contribution of WTAs to growth at sites of infection.
Moreover, the efficacy of WTA inhibitors on bacterial growth
in biological conditions has not been reported.
In this study, tunicamycin, which inhibits TarO (the first
enzyme in WTA biosynthesis) and shuts off WTA production,
was found to reduce the number of bacteria in vitreous humor
(VH). Furthermore, targocil, which is a bacteriostatic agent in
growth media, can kill S. aureus in VH. One explanation of the
observed decrease in S. aureus viability may be that bacteria
treated with tunicamycin or targocil, thereby having inhibited
WTA production, are weakened against an unidentified killing
mechanism in VH. To confirm this hypothesis, we used a
genetic mutant deficient in tarO expression. VH can kill this
mutant, which lacks WTA. In addition, another tarO mutant
that has been engineered to express only tarO when IPTG was
added was tested. Using this strain, we were able to reverse
this effect by inclusion of IPTG, confirming that WTAs are not
just required for growth but also survival in VH. These findings
show that WTAs play an essential role in protecting S. aureus
in this in vivo environment.
Microscopic examination of WTA-null mutants treated in
VH revealed an increase in cell size, irregularly shaped cells,
and aberrant placement of cell division sites. These morpho-
logic changes were not observed in WTA mutants grown in
laboratory media or in the wild-type strain grown in either VH
or BHI. Previous studies have demonstrated that WTA mutants
show rough surfaces, but changes in cell size were not re-
ported.28 The precise mechanism for the observed defects in
the cell envelope and cell division functions cannot yet be
deduced from these data. As several reports have demonstrated
that mutants of cell wall components such as MsrR- or penicil-
lin-binding proteins show enlarged cells and aberrant place-
ment of cell division sites,30,31 VH may influence the cell wall
components of WTA-deficient mutants.
Biochemical investigation has shown that vitreous humor
contains a variety of substances vital for bacterial growth.32,33
However, antimicrobial agents such as lysozyme and cationic
antimicrobial peptides (CAMPs), which are important compo-
nents of the innate response, are also present in the vitreous
body.34–36 It is possible that these antimicrobial agents in VH
act more effectively against WTA-null mutants than against
wild-type S. aureus. However, others have reported that the
antimicrobial activity of lysozyme, lactoferrin, and some
CAMPs are not affected by the lack of WTAs.12,28,37 Further-
more, the absence of WTAs in S. aureus causes a selective
increase in bacterial resistance to CAMPs, such as group IIA
phospholipase A2 and human -defensin 3, potentially because
WTAs, which are anionic polymers, may participate in the
binding of CAMPs.28 Other potential VH antimicrobial agents
are proteases. A recent report demonstrated that some pro-
teases could exhibit antimicrobial activity.38–40 In our study, a
heat-stable, protease-K–sensitive component in VH was di-
rectly or indirectly responsible for VH killing activity. Serine
protease inhibitors selectively rescued WTA-deficient mutants
from the killing action of VH. Serine proteases contain an
activated serine residue at the active site, and some serine
proteases could have antimicrobial activity.39,40 Although
CAMPs function by disrupting anionic bacterial surfaces, the
serine proteases may degrade bacterial proteins including vir-
ulence factors.40 Since WTAs are located outside of the cell
wall and are covalently linked to peptidoglycan, they could
protect the cell wall or membrane from protease cleavage. We
re-examined possible direct antimicrobial activity of common
serine proteases that could contribute to VH antimicrobial
activity for S. aureus. Plasmin, thrombin, or neutrophil elastase
did not show antimicrobial activity against either wild-type or
WTA mutants (data not shown). Further investigation is
needed to determine precisely what synergizes with the inhib-
itors of WTA in VH.
In conclusion, we have found that WTA-deficient mutants
cannot establish endophthalmitis and that these mutants are
incapable of growth in the eye. This observation is consistent
FIGURE 6. Role of WTA in a mouse
endophthalmitis model. (A) ERG. Retinal
responsiveness of eyes infected with
RN6390 (F) or RN6390tarO (E).
RN6390tarO is significantly less able to
establish endophthalmitis and cause vi-
sion loss. Data represent the mean 
SEM (n  8). **P  0.001 (in compari-
son to eyes infected with RN6390). (B)
Number of viable RN6390 (F) or
RN6390tarO (E) recovered from
mouse eyes. The numbers of recovered
RN6390tarO reduced significantly
from 24 to 48 hours after inocula-
tion. Data are expressed as the
mean  SEM (n  4 – 8). *P  0.05,
**P  0.001 (in comparison to the num-
ber of RN6390tarO at 0 hours). (C)
Histologic analysis. At 48 hours,
eyes infected with RN6390 showed
disruption of the retinal layers
(left). In contrast, the retinas of
eyes infected with RN6390tarO
had a normal appearance (right).
Hematoxylin and eosin; magnifica-
tion, 4.
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with our in vitro data using VH, which collectively show that
WTAs are necessary for growth and survival of S. aureus in the
eye. Previous animal experiments have shown that WTAs play
critical roles in tissue adhesion to establish infections.12,13,15
Collectively, these observations implicate the WTA biosyn-
thetic pathway in S. aureus as a useful target to treat or prevent
endophthalmitis and other infections.
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